Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin novel formulations in Sickle Cell Disease
NCT05098028Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of rifaximin in sickle cell disease (SCD), sponsored by Valeant Pharmaceuticals. Started Mar 2022; status: completed.
02
Drugs
rifaximin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05098028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098028.